www.easy-to-use-pharmacy.com
- US Toll free:
- Regular US:
- UK:
- Categories list
-
- Alcoholism
- Alzheimer's And Parkinson's
- Analgesics
- Anti-inflammatories
- Antiallergic
- Antibiotics
- Anticonvulsants
- Antidepressants
- Antifungals
- Antiparasitic
- Antivirals
- Arthritis
- Asthma
- Birth Control
- Cancer
- Cardiovascular Diseases
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Care
- Gastrointestinal Tract
- HIV
- Hypertension
- Men's Health
- Mental Disorders
- Migraine
- Muscle Relaxants
- Neurological Disorders
- Obesity
- Osteoporosis
- Respiratory Tract
- Skin Care
- Stop Smoking
- Surgery
- Urinary Tract
- Women's Health
Generic Zidovudine - Combivir, Retrovir
Generic Combivir
Lamivudine - Zidovudine 150mg + 300mg
Generic Combivir is in a group of medicines called reverse transcriptase inhibitors. It is used for treating HIV infection in combination with other medicines.
$1.44
Buy now!
Generic Retrovir
Generic Retrovir is used for treating HIV infection when used along with other medicines. It is also used with other medicines to help prevent women from passing the HIV virus to the fetus during pregnancy.
$1.17
Buy now!
Choose Your language:
- Testimonials
-
You have been fabulous to work with and I will clearly recommend your service and use it again myself.
Read more »
-
- Aurobindo Pharma gets US FDA approval for lamivudine & zidovudine tabs - pharmabiz.com
- Moneycontrol
- Lupin Launches Generic Combivir Tablets - RTT News
- Moneycontrol
- Lupin, Aurobindo get USFDA nod for HIV drug - Economic Times
- Lupin, Aurobindo get USFDA nod for HIV drugEconomic TimesLupin Pharmaceuticals Inc, a subsidiary of Lupin Ltd, has received final approval from US Food and Drug Administration (USFDA) for its generic Lamivudine and Zidovudine combination tablet in strength of 150mg/300 mg, Lupin said in a statement
- HIV positive patients face bleak future - NewsDay
- HIV positive patients face bleak futureNewsDayZimbabwe started phasing out the combination anti-retroviral treatment (ARV) Stavudine, Lamivudine and Nevirapine as its first-line option for the national programme, replacing it with the less toxic Tenofovir and Zidovudine-based regimens
- LANDMARK HIV DRUG'S PATENT EXPIRES TODAY - U-T San Diego
- LANDMARK HIV DRUG'S PATENT EXPIRES TODAYU-T San DiegoThe FDA approved Combivir (lamivudine/zidovudine) in 1997, greatly changing the treatment of HIV/AIDS
 |
Bookmark this site |
|---|
 |
Subscribe to the News |
|---|
